Loading clinical trials...
Loading clinical trials...
Cold Atmospheric Plasma Device for the Treatment of Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients - Open-Label Extension Study
Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearance will be measured. Photographs and dermatologist impressions will be used to measure treatment response.
Age
4 - 21 years
Sex
ALL
Healthy Volunteers
No
Medical University of South Carolina
Charleston, South Carolina, United States
Start Date
September 18, 2023
Primary Completion Date
February 1, 2026
Completion Date
February 1, 2026
Last Updated
June 19, 2025
40
ESTIMATED participants
Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
DEVICE
Lead Sponsor
Medical University of South Carolina
Collaborators
NCT05536882
NCT05634460
NCT05409365
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions